Mont-Saint-Guibert, Belgium - Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell-based therapies, today announced that it will host a Research & Development Day on Monday, March 18 in New York City, from 12:00 p.m. to 2:00 p.m. ET. 

Members of the Celyad leadership team will provide an overview of the recent breakthroughs in the R&D pipeline, updates on key clinical trials and the Company's cell therapy manufacturing capabilities. In addition, Celyad will unveil its next-generation NKG2D preclinical program CYAD-02 as well as the Company’s proprietary non-gene edited allogeneic platforms including the CYAD-200 series of shRNA-based CAR-T programs.

Webcast Information

The full program will be webcast live and can be accessed here. Please connect to the webcast several minutes prior to the start of the event to ensure the connection. It will also be available, post-event, in the “Events & Webcasts” section of the Company’s website.

Download press release(s)

Press release

73.49 Ko

Communiqué de presse

106.25 Ko

Persbericht

90.90 Ko

Celyad’s 2019 R&D Day Highlights shRNA Platform and Pipeline of Next-generation NKG2D-base...

Next News

Celyad’s 2019 R&D Day Highlights shRNA Platform and Pipeline of Next-generation NKG2D-base...